Dr Reddys Laboratories (RDY) Revenue (2009 - 2026)

Dr Reddys Laboratories has reported Revenue for 18 years, with the latest figure at $852.5 million in Q2 2026.

• On a quarterly basis, Revenue fell 14.62% year-over-year to $852.5 million in Q2 2026; TTM through Jun 2026 was $3.7 billion, a 6.71% decrease from a year earlier, with the FY2026 full-year figure at $3.6 billion, down 7.05% from the prior year.
• Revenue was $852.5 million for Q2 2026 at Dr Reddys Laboratories, up from $822.2 million in the prior quarter.
• The five-year high for Revenue was $1.0 billion in Q3 2025, with the low at $676.4 million in Q2 2022.
• Average Revenue over 5 years is $871.8 million, with a median of $852.7 million recorded in 2026.
• The sharpest annual moves came in 2023 and 2026: Revenue gained 22.42% in 2023, then decreased 16.3% in 2026.
• Over 5 years, Revenue stood at $767.0 million in 2022, then climbed by 12.97% to $866.5 million in 2023, then rose by 14.25% to $990.0 million in 2024, then declined by 1.01% to $980.0 million in 2025, then dropped by 13.01% to $852.5 million in 2026.
• The last three Revenue figures came in at $852.5 million (Q2 2026), $822.2 million (Q1 2026), and $980.0 million (Q4 2025), per Business Quant data.